# NKT2152-101 (NCT05119335)

> A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: NKT2152
- Indication: advanced clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05119335
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: NiKang Therapeutics, Inc.
- Conditions: ccRCC; Clear Cell Renal Cell Carcinoma; Kidney Cancer; Kidney Neoplasms; Renal Cancer; Renal Neoplasms; Recurrent Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Refractory Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Hypoxia; Renal Cell Carcinoma; Hypoxia Inducible Factor (HIF); HIF2α Inhibitor; Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha); Hypoxia Inducible Factor 2α (HIF-2α); Clear Cell
- Interventions: Oral NKT2152
- Enrollment: 120
- Primary outcome: Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period (first 21 days of dosing) in the Dose Escalation Phase (Phase 1)
- Primary outcome: Recommended Doses for Expansion (RDEs) Determined in the Dose Escalation Phase (Phase 1)
- Primary outcome: Objective Response Rate (ORR) determined by the Investigator in the Dose Expansion Phase (Phase 2)
- Primary outcome: Recommended Phase 2 Dose (RP2D)

## Indexed commentary on NKT2152-101 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nkt2152-101-nct05119335